ArticleJournal of the American Medical Informatics Association : JAMIA2011
Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis.
Article in Journal of the American Medical Informatics Association : JAMIA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Article
- Unraveling Structural Alerts in Marketed Drugs for Improving Adverse Outcome Pathway Framework of Drug-Induced QT Prolongation.International journal of molecular sciences · 2023Article
- Evaluating Drug Risk Using GAN and SMOTE Based on CFDA's Spontaneous Reporting Data.Journal of healthcare engineering · 2021Article
- Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions.Drug safety · 2020Article
- Extraction of Information Related to Drug Safety Surveillance From Electronic Health Record Notes: Joint Modeling of Entities and Relations Using Knowledge-Aware Neural Attentive Models.JMIR medical informatics · 2020Article
- Predicting potential adverse events using safety data from marketed drugs.BMC bioinformatics · 2020Article
- Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports.BMC medical informatics and decision making · 2019Article
- Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management.Drug discovery today · 2019Review
- Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media.Briefings in bioinformatics · 2018Review
- Mining e-cigarette adverse events in social media using Bi-LSTM recurrent neural network with word embedding representation.Journal of the American Medical Informatics Association : JAMIA · 2018Article
- Toward multimodal signal detection of adverse drug reactions.Journal of biomedical informatics · 2017Article
- A curated and standardized adverse drug event resource to accelerate drug safety research.Scientific data · 2016Article
- Relationships Between Pharmacovigilance, Molecular, Structural, and Pathway Data: Revealing Mechanisms for Immune-Mediated Drug-Induced Liver Injury.CPT: pharmacometrics & systems pharmacology · 2015Article
- 3D pharmacophoric similarity improves multi adverse drug event identification in pharmacovigilance.Scientific reports · 2015Article
- Portable automatic text classification for adverse drug reaction detection via multi-corpus training.Journal of biomedical informatics · 2015Article
- Article
- A time-indexed reference standard of adverse drug reactions.Scientific data · 2014Article
- Similarity-based modeling applied to signal detection in pharmacovigilance.CPT: pharmacometrics & systems pharmacology · 2014Article
- Similarity-based modeling in large-scale prediction of drug-drug interactions.Nature protocols · 2014Article
- Toward enhanced pharmacovigilance using patient-generated data on the internet.Clinical pharmacology and therapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAdverse drug events (ADE) cause considerable harm to patients, and consequently their detection is critical for patient safety. The US Food and Drug Administration maintains an adverse event reporting system (AERS) to facilitate the detection of ADE in drugs. Various data mining approaches have been developed that use AERS to detect signals identifying associations between drugs and ADE. The signals must then be monitored further by domain experts, which is a time-consuming task.
objectiveTo develop a new methodology that combines existing data mining algorithms with chemical information by analysis of molecular fingerprints to enhance initial ADE signals generated from AERS, and to provide a decision support mechanism to facilitate the identification of novel adverse events.
resultsThe method achieved a significant improvement in precision in identifying known ADE, and a more than twofold signal enhancement when applied to the ADE rhabdomyolysis. The simplicity of the method assists in highlighting the etiology of the ADE by identifying structurally similar drugs. A set of drugs with strong evidence from both AERS and molecular fingerprint-based modeling is constructed for further analysis.
conclusionThe results demonstrate that the proposed methodology could be used as a pharmacovigilance decision support tool to facilitate ADE detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.